Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT: OPM-101 + Pembrolizumab in Advanced Melanoma
NCT07040436Phase 2Not yet recruiting
- Sponsor
- Oncodesign Precision Medicine
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of OPM-101 in melanoma, sponsored by Oncodesign Precision Medicine. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
OPM-101
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07040436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040436.